← SynDRA
BORTEZOMIB
SynDRA canonical compound SYN0004189 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PSMB5 |
|---|
| Mechanism of action | NFKB pathway inhibitor |
|---|
| Indication | mantle cell lymphoma (MCL) | multiple myeloma |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- PSMB2
- PSMB5
- PSMB1
- PSMA1
- PSMB8
- PSMD1
- PSMB9
- PSMB10
- PSMA2
- PSMA3
- PSMB11
- PSMB3
Mechanisms of action (all sources)
- proteasome inhibitor
- NFKB pathway inhibitor
- PSMD1 INHIBITOR
- PSMB2 INHIBITOR
- PSMB1 INHIBITOR
- PSMB5 INHIBITOR
- PSMB8 INHIBITOR
- PSMB9 INHIBITOR
- PSMB6 INHIBITOR
- PSMD14 INHIBITOR
- PSMA1 INHIBITOR
- PSMA2 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- NR1I2
- ESR1
- CASP7
- ADAM17
- MC3R
- MMP3
- MMP2
- MMP12
- MMP1
- MME
- MLNR
- MC4R
- MAOA
- MMP8
- KLKB1
- KCNH2
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- MMP7
- NPY1R
- MYC
- HIF1A
- TDP1
- TBXA2R
- TASP1
- SLC6A4
- SLC6A3
- SLC6A2
- SLC29A1
- SETD7
- REN
- PTGS2
- PLG
- PLAT
- PGR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ANDR
- MITF
- TFE3
- SYUA
- SYK
- SNCA
- SMAD3
- SMAD2
- RARA
- PRGR
- PPARD
- PARP1
- NSD2
- NF2L2
- KSYK
- ATAD5
- IFNG
- IFNB1
- HSPB1
- HLAB
- ESRRA
- ESR2
- CREB1
- CP3A4
- CP2CJ
- CP1A2
- CP19A
- ATXN2
- TP53
Drug classes
- Proteasome Inhibitors
- Antineoplastic Agents
- Proteasome Inhibitor
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- Boruzu
- VELCADE
- Velcade
- LDP-341
- PS-341
- velcade
- radiciol
- Bortezomib hydrate
- NSC-681239
- Bortezomib (PS-341)
- UNII-69G8BD63PP
- MLN-341
- CHEMBL325041
- 69G8BD63PP
- Boronic acid,
- DPBA
- PROSCRIPT BORONIC ACID
- LPD-341
- VELCADE (TN)
- Pyz-Phe-boroLeu
- Bortezomib(JAN/USAN/INN)
- Velcade, MG-341, PS-341, Bortezomib
- Bortezomib (Proteasome inhibitor)
- Peptide boronate
- Ps 341
- LDP 341
- Bortezomib accord
- NSC 681239
- Bortezomib (Velcade)
- MG-341
- CHEBI:52717
- NSC681239
- NCGC00242506-02
- S1013
- Velcade (TN)
- CAS-179324-69-7
- C19H25BN4O4
Reported adverse events
- Abdominal pain
- Acute respiratory distress syndrome
- Anaphylactic reaction
- Asthenia
- Chills
- Cholestasis
- Constipation
- Dehydration
- Diplopia
- Dizziness
- Fatigue
- Headache
Look up BORTEZOMIB in the interactive SynDRA portal →